NewAmsterdam Pharma Company NV (NASDAQ: NAMS) on Friday, soared 4.70% from the previous trading day, before settling in for the closing price of $17.02. Within the past 52 weeks, NAMS’s price has moved between $8.64 and $26.35.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -28.76% over the last five years. The company achieved an average annual earnings per share of -8.28%. With a float of $43.53 million, this company’s outstanding shares have now reached $82.47 million.
The firm has a total of 29 workers. Let’s measure their productivity. In terms of profitability, gross margin is 99.74%, operating margin of -2794.53%, and the pretax margin is -3072.19%.
NewAmsterdam Pharma Company NV (NAMS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of NewAmsterdam Pharma Company NV is 51.64%, while institutional ownership is 37.72%. The most recent insider transaction that took place on Oct 01 ’24, was worth 707,400. In this transaction Chief Accounting Officer of this company sold 45,000 shares at a rate of $15.72, taking the stock ownership to the 0 shares. Before that another transaction happened on Oct 01 ’24, when Company’s Officer proposed sale 45,000 for $17.29, making the entire transaction worth $778,050.
NewAmsterdam Pharma Company NV (NAMS) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.54 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.49) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.28% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
NewAmsterdam Pharma Company NV (NAMS) is currently performing well based on its current performance indicators. A quick ratio of 9.83 was reported for the most recent quarter.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Analysing the last 5-days average volume posted by the [NewAmsterdam Pharma Company NV, NAMS], we can find that recorded value of 0.35 million was better than the volume posted last year of 0.26 million. As of the previous 9 days, the stock’s Stochastic %D was 18.15%. Additionally, its Average True Range was 0.90.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 41.81%, which indicates a significant increase from 38.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.50% in the past 14 days, which was lower than the 47.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.20, while its 200-day Moving Average is $19.37. Now, the first resistance to watch is $18.29. This is followed by the second major resistance level at $18.76. The third major resistance level sits at $19.65. If the price goes on to break the first support level at $16.93, it is likely to go to the next support level at $16.04. Now, if the price goes above the second support level, the third support stands at $15.57.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
Market capitalization of the company is 1.68 billion based on 90,015K outstanding shares. Right now, sales total 14,090 K and income totals -176,940 K. The company made 2,280 K in profit during its latest quarter, and -39,010 K in sales during its previous quarter.
